Stock Analysis
- Switzerland
- /
- Life Sciences
- /
- SWX:TECN
Tecan Group Full Year 2023 Earnings: EPS Beats Expectations
Tecan Group (VTX:TECN) Full Year 2023 Results
Key Financial Results
- Revenue: CHF1.07b (down 6.1% from FY 2022).
- Net income: CHF132.1m (up 9.0% from FY 2022).
- Profit margin: 12% (up from 11% in FY 2022). The increase in margin was driven by lower expenses.
- EPS: CHF10.34 (up from CHF9.53 in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Tecan Group EPS Beats Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 14%.
Looking ahead, revenue is forecast to grow 6.9% p.a. on average during the next 3 years, compared to a 9.4% growth forecast for the Life Sciences industry in Switzerland.
Performance of the Swiss Life Sciences industry.
The company's shares are up 3.3% from a week ago.
Risk Analysis
Before we wrap up, we've discovered 1 warning sign for Tecan Group that you should be aware of.
Valuation is complex, but we're helping make it simple.
Find out whether Tecan Group is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SWX:TECN
Tecan Group
Tecan Group AG provides laboratory instruments and solutions for pharmaceutical, biotechnology and in-vitro diagnostic companies, university research departments, and diagnostic and other laboratories.
Excellent balance sheet and good value.